Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN 1840 (formerly WTX 101) met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments
The Cooper Companies has agreed to buy ParaGard, an intrauterine copper contraceptive brand from Teva Pharmaceutical Industries for $1.1 billion...
Treatment of Wilson's disease.
Detailed results from the positive FoCus Phase III trial in Wilson disease showed that ALXN 1840, an investigational once-daily, oral medicine, met its primary endpoint demonstrating three-times greater copper mobilisation from tissues compared to the standard of care (SoC) arm (Least Square Mean Difference [LSM Diff] 2.18 µmol/L; p< 0.0001), including in patients who had been treated previously for an average of 10 years.
Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
Trientine capsules are indicated for the treatment of Wilson's disease in patients intolerant to D-Penicillamine therapy, in adults, adolescents and children aged 5 years or older.